Recent News

• 02.11.2026 - Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Updates on Tuesday, February 24, 2026
• 02.05.2026 - Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma
• 01.16.2026 - Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
• 12.19.2025 - Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
• 11.21.2025 - Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
• 11.06.2025 - Iovance Biotherapeutics Highlights Business Achievements, Pipeline Milestones, and Third Quarter 2025 Results
• 11.03.2025 - Iovance Biotherapeutics Reports Potential Best-in-Class Clinical Data for Lifileucel TIL Cell Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC)
• 10.23.2025 - Iovance Biotherapeutics to Host Third Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, November 6, 2025

Recent Filings

• 02.09.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 01.09.2026 - EX-99.1 EX-99.1
• 01.09.2026 - 8-K Current report
• 12.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.12.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 11.12.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 11.06.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]